«
June 19, 2006
Set-Up
The emergence, several years after his sudden departure from FBN, of pot-smoking hippie demonstrators experimenting with a melange of new 'psychedelics' while urging both radical social change and an end to the Viet Nam war gave Richard Nixon one of the major items on his 1968 wish list: a federal police agency he could control. Although Watergate ultimately frustrated him, the DEA and NIDA-- both outgrowths of his sweeping 1970 Controlled Substances Act (CSA)–– became important to Ronald Reagan's first-term decision to intensify Nixon's drug war. Since then, the DEA has retained Anslinger's authoritative role as the major 'official' source of drug information, while NIDA has become sponsor of 85% of academic studies of 'drugs of abuse' and thus able to skew both their design and interpretation in support of our never-admitted policy of prohibition.
We now have an utterly dishonest 'control' policy which three quarters of the general public see as a failure beyond fixing; yet federal bureaucrats are free to spend billions boosting as successful. Beyond that, our powerless 'drug czar,' is merely a purveyor of propaganda fashioned from selected data supplied by a self-interested federal police agency and augmented by 'research' sponsored by another 'scientific' agency created to study a 'disease' (drug abuse) for which objective diagnostic criteria are lacking and total abstinence has been decreed the only acceptable goal of treatment. Among the few reliable statistics allowing a peek at what four decades of such insanity have actually accomplished: over two million prisoners in our jails and prisons, the arrest of over three quarters of a million people each year for cannabis violations, and several thriving illegal drug markets which can't be precisely measured by standard econometric techniques–– precisely because they are illegal.
This rant is intended as background for the deconstruction of a recent Op-ed by Professor Mark Kleiman, who has made a comfortable living and achieved a considerable academic success by teaching drug policy 'analysis,' most recently at UCLA.
Doctor Tom